Mineralys Therapeutics Inc
MLYS
Company Profile
Business description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Contact
150 North Radnor Chester Road
Suite F200
RadnorPA19087
USAT: +1 888 378-6240
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
51
Stocks News & Analysis
stocks
Is AUB an opportunity after shares plunge 17%?
After a takeover bid was withdrawn shares dropped to below the pre-bid price.
stocks
Attractive ASX listed income opportunity
A high forward distribution yield may entice income investors.
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
Finding value in some of the ASX’s worst recent performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.50 | 11.10 | 0.13% |
| CAC 40 | 8,097.00 | 25.71 | -0.32% |
| DAX 40 | 23,589.44 | 247.35 | -1.04% |
| Dow JONES (US) | 47,289.33 | 427.09 | -0.90% |
| FTSE 100 | 9,702.53 | 17.98 | -0.18% |
| HKSE | 26,032.89 | 0.37 | -0.00% |
| NASDAQ | 23,275.92 | 89.76 | -0.38% |
| Nikkei 225 | 49,303.45 | 0.17 | 0.00% |
| NZX 50 Index | 13,502.77 | 54.28 | 0.40% |
| S&P 500 | 6,812.63 | 36.46 | -0.53% |
| S&P/ASX 200 | 8,579.70 | 14.50 | 0.17% |
| SSE Composite Index | 3,894.29 | 19.71 | -0.50% |